A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions

Severe infusion reactions (SIRs) at rates of 5% or less are known side effects of biological agents, including mAbs such as cetuximab. There are currently no prospectively validated risk factors to aid physicians in identifying patients who may be at risk of experiencing an SIR following administrat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maier, Sabine, Chung, Christine H, Morse, Michael, Platts-Mills, Thomas, Townes, Leigh, Mukhopadhyay, Pralay, Bhagavatheeswaran, Prabhu, Racenberg, Jan, Trifan, Ovidiu C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312116/
https://www.ncbi.nlm.nih.gov/pubmed/25296628
http://dx.doi.org/10.1002/cam4.333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312116/
https://www.ncbi.nlm.nih.gov/pubmed/25296628
http://dx.doi.org/10.1002/cam4.333

Ejemplares similares